Specialty code 183500000X · Palo Alto, CA
NPI
1659748960
Since 2015
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
3801 Miranda Ave # 119
Palo Alto, CA, 94304
Phone (650) 493-5000
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$307K
2,689 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Linda T Nguyen prescribed most often to Medicare patients was Atorvastatin Calcium, with 338 prescriptions and refills. In total Linda T Nguyen wrote 2,689 Medicare prescriptions that cost $307K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-30.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 338 | 1,119 | 129 | $4,093 |
| Glipizide Generic | 262 | 860 | 101 | $3,364 |
| Metformin Hcl Generic | 229 | 760 | 81 | $2,895 |
| Metformin Hcl Er Metformin Hcl | 206 | 686 | 81 | $2,082 |
| Insulin Glargine-Yfgn Generic | 149 | 408 | 68 | $19K |
| Jardiance Empagliflozin | 132 | 422 | 51 | $75K |
| Humulin N Insulin Nph Human Isophane | 126 | 368 | 54 | $22K |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 126 | 402 | 53 | $3,479 |
| Ozempic Semaglutide | 106 | 111 | 18 | $80K |
| Amlodipine Besylate Generic | 87 | 276 | 32 | $1,054 |
| Lisinopril Generic | 86 | 287 | 34 | $1,037 |
| Humulin R Insulin Regular, Human | 68 | 188 | 28 | $9,786 |
| Glipizide Er Glipizide | 62 | 206 | 23 | $1,660 |
| Simvastatin Generic | 58 | 193 | 21 | $677 |
| Losartan Potassium Generic | 56 | 187 | 22 | $677 |
Brand drugs: 766 claims; generic drugs: 1,652 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Linda T Nguyen were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.